Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EV403
- Development stage
- Preclinical
- Lead developer
- EV Therapeutics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
EV403 is an investigational, preclinical-stage therapeutic candidate being developed by EV Therapeutics for the treatment of hepatic cancer. It utilizes the company's proprietary extracellular vesicle (EV) platform, which engineers exosomes to serve as targeted delivery vehicles for therapeutic payloads. By leveraging the natural biocompatibility and cell-targeting capabilities of EVs, EV403 is designed to deliver its payload directly to liver cancer cells, potentially improving therapeutic efficacy while reducing systemic side effects. It is part of a broader pipeline of EV-based therapies focused on gastrointestinal and hepatic malignancies.
Beyond the preview
Go deeper on EV403.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EV403.